{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:47:08Z","timestamp":1791726428307,"version":"4.3.4"},"reference-count":24,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced Therapy Medicinal Products (ATMPs) for human use have advanced globally with the rapid adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapies in haemato-oncology. CAR-T cell therapy and ATMPs have unique, significant acute and chronic toxicities, and appropriate patient care is crucial. Significant challenges, including the need for nurse education and training, accompany optimal patient success and benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objectives\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to describe nurses\u2019 training needs in relation to ATMP management and patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional online survey was performed by the European Society for Blood and Marrow Transplantation, based on a previously tested questionnaire developed in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"findings\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>109 complete responses from 86 different centers from 24 countries were returned (1207 distributed). Over 1\/3 reported experience delivering licensed ATMPs (CAR-T). High-priority training areas included a general introduction to ATMPs, toxicity management, product-specific information, and regulatory frameworks for ATMPs. A clear need for ATMP-specific training exists and is regarded as important. Training prior to implementation is key and should be supported by ongoing competency maintenance. Counseling, patient support, and long-term follow-up are identified for future training and opportunities for nurse experience sharing in this rapidly evolving field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.46989\/001c.124593","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T09:41:49Z","timestamp":1731663709000},"source":"Crossref","is-referenced-by-count":3,"title":["Nurses\u2019 reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT"],"prefix":"10.46989","volume":"6","author":[{"given":"Michelle","family":"Kenyon","sequence":"first","affiliation":[{"name":"Department of Haematological Medicine, 4th Floor Hambledon Wing West, King\u2019s College Hospital NHS Foundation Trust, Denmark Hill, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Jayne","family":"Liptrott","sequence":"additional","affiliation":[{"name":"Nursing Development and Research Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), via Gallino 12, 6500, Bellinzona, Switzerland"},{"name":"Department of Nursing, Regional Hospital of Bellinzona e Valli, Ente Ospedaliero Cantonale (EOC), via Gallino 12, 6500, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kisch","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden"},{"name":"Institute of Health Sciences, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarl","family":"Mooyaart","sequence":"additional","affiliation":[{"name":"EBMT Leiden Statistical Unit, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Piepenbroek","sequence":"additional","affiliation":[{"name":"EBMT Leiden Study Unit, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphna","family":"Hutt","sequence":"additional","affiliation":[{"name":"Department of Paediatric Hematology-Oncology and BMT, Edmond and lily Safra Children Hospital, Sheba Medical center, Ramat-Gan 5265601 Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Salcedo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, Spain; Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro-Segovia Arana. Calle Joaqu\u00edn Rodrigo 2, 28222 Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Dept of Hematology, IRCCS San Raffaele Scientific Institute, 20135 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Chabannon","sequence":"additional","affiliation":[{"name":"Centre de Th\u00e9rapie Cellulaire. Institut Paoli-Calmettes Comprehensive Cancer Centre & module Bioth\u00e9rapies du Centre d\u2019Investigations Cliniques de Marseille, Inserm CBT-1409, Aix-Marseille Universit\u00e9, AP-HM, Institut Paoli-Calmettes. Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Ellard","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Murray","sequence":"additional","affiliation":[{"name":"Haematology and Transplant Unit The Christie NHS FT, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"ref1","article-title":"Resources","author":"Advanced Therapy Treatment Centres (ATTC)","year":"2020"},{"issue":"3","key":"ref2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000526786","article-title":"Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment","volume":"50","author":"P. Berg","year":"2022","journal-title":"Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie"},{"key":"ref3","series-title":"The EBMT\/EHA CAR-T Cell Handbook","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-3-030-94353-0_42","article-title":"Educational Needs for Cell Processing Facility Personnel","author":"B. Calmels","year":"2022"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"896685","DOI":"10.3389\/fimmu.2022.896685","article-title":"Clinical Investigations of CAR-T Cell Therapy for Solid Tumors","volume":"13","author":"K. Chen","year":"2022","journal-title":"Frontiers in immunology"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"A. Cordeiro","year":"2020","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"8","key":"ref6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.bbmt.2020.03.021","article-title":"Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program","volume":"26","author":"S. O. Dulan","year":"2020","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"3","key":"ref7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s44228-022-00004-8","article-title":"The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities","volume":"4","author":"R. Ellard","year":"2022","journal-title":"Clinical hematology international"},{"issue":"Suppl 1","key":"ref8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12913-017-2341-x","article-title":"The hub-and-spoke organization design: an avenue for serving patients well","volume":"17","author":"J. K. Elrod","year":"2017","journal-title":"BMC health services research"},{"key":"ref9","article-title":"Introducing the Immune Effector Cells Forum for Nurses","author":"European Blood and Marrow Transplantation Society","year":"2023"},{"key":"ref10","article-title":"Advanced therapy medicinal products: Overview","author":"European Medicines Agency","year":"2023"},{"key":"ref11","article-title":"International Standards for hematopoietic cellular therapy product collection, processing, and Administration","author":"Foundation for the Accreditation of Cellular Therapy (FACT)","year":"2021","edition":"8, Version 8.1"},{"key":"ref12","article-title":"CAR (Chimeric Antigen Receptor) T-Cell Therapy: A Resource for Healthcare Professionals","author":"Haematology Nurses and Healthcare Professionals (HNHCP)","year":"2022"},{"issue":"3","key":"ref13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"P. J. Hayden","year":"2022","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"3","key":"ref14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000511678","article-title":"Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion","volume":"5","author":"D. Horgan","year":"2020","journal-title":"Biomedicine hub"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"F. L. Locke","year":"2019","journal-title":"The Lancet. Oncology"},{"issue":"1","key":"ref16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bjh.14384","article-title":"The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products","volume":"176","author":"M. W. Lowdell","year":"2017","journal-title":"British journal of haematology"},{"issue":"7","key":"ref17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"J. R. Passweg","year":"2021","journal-title":"Bone marrow transplantation"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2515135520944355","DOI":"10.1177\/2515135520944355","article-title":"Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites","volume":"8","author":"M. Pillai","year":"2020","journal-title":"Therapeutic advances in vaccines and immunotherapy"},{"issue":"10","key":"ref19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"K. Rejeski","year":"2023","journal-title":"Blood"},{"key":"ref20","article-title":"The UK training landscape in advanced therapies for the NHS","author":"C. Roberts","year":"2020","journal-title":"NHS Blood and Transplant & Catapult"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","volume":"39","author":"B. Santomasso","year":"2019","journal-title":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"A. Shimabukuro-Vornhagen","year":"2018","journal-title":"Journal for immunotherapy of cancer"},{"issue":"2","key":"ref23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1188\/19.CJON.S1.20-26","article-title":"Building a Program: Implications for Infrastructure, Nursing Education, and Training for CAR T-Cell Therapy","volume":"23","author":"L. Taylor","year":"2019","journal-title":"Clinical journal of oncology nursing"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","author":"N. Verdun","year":"2024","journal-title":"The New England journal of medicine"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/124593-nurses-reported-training-needs-for-advanced-cell-therapies-a-survey-on-behalf-of-the-nurses-group-of-the-ebmt","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:40:08Z","timestamp":1791726008000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/124593-nurses-reported-training-needs-for-advanced-cell-therapies-a-survey-on-behalf-of-the-nurses-group-of-the-ebmt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.124593","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}